Statistik Asas
| CIK | 1720446 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Zepp Health Corporation - Depositary Receipt (Common Stock)
SEC Filings (Chronological Order)
Halaman ini menyediakan senarai kronologi lengkap bagi Pemfailan SEC, tidak termasuk pemfailan pemilikan yang kami sediakan di tempat lain.
| August 4, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of August 2025 Commission File Number: 001-38369 Zepp Health Corporation (Registrant’s Name) Edisonweg 44 – B08, 4207 HG Gorinchem, The Netherlands (Address of principal executive offices) Indicat |
|
| August 4, 2025 |
Zepp Health Corporation Reports Second Quarter 2025 Unaudited Financial Results Exhibit 99.1 Zepp Health Corporation Reports Second Quarter 2025 Unaudited Financial Results MILPITAS, Calif., August 3, 2025 /PRNewswire/ - Zepp Health Corporation (“Zepp” or the “Company”) (NYSE: ZEPP) today announced its unaudited financial results for the second quarter of 2025. Second Quarter 2025 Financial and Operating Highlights: · Revenue reached US$59.4 million, representing 46.2% year-o |
|
| May 21, 2025 |
Exhibit 12.1 Certification by the Principal Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 I, Wang Wayne Huang, certify that: 1. I have reviewed this annual report on Form 20-F of Zepp Health Corporation (the “Company”); 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the |
|
| May 21, 2025 |
Exhibit 13.2 Certification by the Chief Financial Officer Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 In connection with the Annual Report of Zepp Health Corporation (the “Company”) on Form 20-F for the fiscal year ended December 31, 2024 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Leon Cheng Deng, Chief Financial Officer of the Company, |
|
| May 21, 2025 |
Exhibit 13.1 Certification by the Principal Executive Officer Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 In connection with the Annual Report of Zepp Health Corporation (the “Company”) on Form 20-F for the fiscal year ended December 31, 2024 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Wang Wayne Huang, Chief Executive Officer of the Com |
|
| May 21, 2025 |
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM Exhibit 15.3 CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM We consent to the incorporation by reference in Registration Statements No. 333-226665 and No. 333-269830 on Form S-8 of our report dated May 21, 2025, relating to the consolidated financial statements of Jiangsu Yitong High-tech Co., Ltd. included in this Amendment No. 1 to the Annual Report on Form 20-F for the year ended Dece |
|
| May 21, 2025 |
Exhibit 12.2 Certification by the Chief Financial Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 I, Leon Cheng Deng, certify that: 1. I have reviewed this annual report on Form 20-F of Zepp Health Corporation (the “Company”); 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the state |
|
| May 21, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 20-F/A (Amendment No. 1) (Mark One) ¨ REGISTRATION STATEMENT PURSUANT TO SECTION 12(B) OR 12(G) OF THE SECURITIES EXCHANGE ACT OF 1934 OR x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024. OR ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D |
|
| May 20, 2025 |
Zepp Health Corporation Reports First Quarter 2025 Unaudited Financial Results Exhibit 99.1 Zepp Health Corporation Reports First Quarter 2025 Unaudited Financial Results MILPITAS, Calif., May 19, 2025 /PRNewswire/ - Zepp Health Corporation (“Zepp” or the “Company”) (NYSE: ZEPP) today announced its unaudited financial results for the first quarter of 2025. First Quarter 2025 Financial and Operating Highlights: · Revenue reached US$39 million, out of which Amazfit-branded pro |
|
| May 20, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2025 Commission File Number: 001-38369 Zepp Health Corporation (Registrant’s Name) Edisonweg 44 – B08, 4207 HG Gorinchem, The Netherlands (Address of principal executive offices) Indicate b |
|
| April 25, 2025 |
Exhibit 12.1 Certification by the Principal Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 I, Wang Wayne Huang, certify that: 1. I have reviewed this annual report on Form 20-F of Zepp Health Corporation (the “Company”); 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the |
|
| April 25, 2025 |
Exhibit 12.2 Certification by the Chief Financial Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 I, Leon Cheng Deng, certify that: 1. I have reviewed this annual report on Form 20-F of Zepp Health Corporation (the “Company”); 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the state |
|
| April 25, 2025 |
Exhibit 11.2 ZEPP HEALTH CORPORATION AMENDED AND RESTATED Statement of PolicIES Governing Material non-public Information and The Prevention of InsideR Trading (AS ADOPTED BY THE BOARD OF DIRECTORS OF ZEPP HEALTH CORPORATION ON Nov.19 , 2023) This Amended and Restated Statement of Policies Governing Material Non-Public Information and the Prevention of Insider Trading (this “Statement”) applies to |
|
| April 25, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 20-F Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 20-F (Mark One) ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(B) OR 12(G) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024. OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) |
|
| April 25, 2025 |
Exhibit 13.2 Certification by the Chief Financial Officer Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 In connection with the Annual Report of Zepp Health Corporation (the “Company”) on Form 20-F for the fiscal year ended December 31, 2024 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Leon Cheng Deng, Chief Financial Officer of the Company, |
|
| April 25, 2025 |
Exhibit 15.2 CONSENT LETTER ToZepp Health Corporation Edisonweg 44 - B08, 4207 HG Gorinchem, The Netherlands April 25, 2025 Dear Sir/Madam: We hereby consent to the reference of our name under the headings “Item 3. Key Information—D. Risk Factors—Risks Related to Our Corporate Structure” and “Item 4. Information on the Company—C. Organizational Structure” in Zepp Health Corporation’s Annual Report |
|
| April 25, 2025 |
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM Exhibit 15.1 CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM We consent to the incorporation by reference in Registration Statement Nos. 333-226665 and 333-269830 on Form S-8 of our report dated April 25, 2025, relating to the financial statements of Zepp Health Corporation appearing in this Annual Report on Form 20-F for the year ended December 31, 2024. /s/ Deloitte Touche Tohmatsu Cert |
|
| April 25, 2025 |
Exhibit 2.5 Description of rights of each class of securities registered under Section 12 of the Securities Exchange Act of 1934 (the “Exchange Act”) American Depositary Shares (“ADSs”) each representing 16 Class A ordinary shares of Zepp Health Corporation (the “we,” “us,” “our company” or “our”) are listed and traded on the New York Stock Exchange and, in connection with this listing (but not fo |
|
| April 25, 2025 |
Exhibit 13.1 Certification by the Principal Executive Officer Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 In connection with the Annual Report of Zepp Health Corporation (the “Company”) on Form 20-F for the fiscal year ended December 31, 2024 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Wang Wayne Huang, Chief Executive Officer of the Com |
|
| March 27, 2025 |
Zepp Health Corporation Reports Fourth Quarter and Full Year 2024 Unaudited Financial Results Exhibit 99.1 Zepp Health Corporation Reports Fourth Quarter and Full Year 2024 Unaudited Financial Results MILPITAS, Calif., March 26, 2025 /PRNewswire/ - Zepp Health Corporation (“Zepp” or the “Company”) (NYSE: ZEPP) today announced its unaudited financial results for the fourth quarter of 2024. Fourth Quarter 2024 Financial and Operating Highlights: · Revenue reached US$59.5 million representing |
|
| March 27, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of March 2025 Commission File Number: 001-38369 Zepp Health Corporation (Registrant’s Name) Huami Global Innovation Center Building B2, Zhong’an Chuanggu Technology Park No. 900 Wangjiang West Roa |
|
| November 19, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November 2024 Commission File Number: 001-38369 Zepp Health Corporation (Registrant’s Name) Huami Global Innovation Center Building B2, Zhong’an Chuanggu Technology Park No. 900 Wangjiang West |
|
| November 19, 2024 |
Zepp Health Corporation Reports Third Quarter 2024 Unaudited Financial Results Exhibit 99.1 Zepp Health Corporation Reports Third Quarter 2024 Unaudited Financial Results MILPITAS, Calif., November 18, 2024 /PRNewswire/ - Zepp Health Corporation (“Zepp” or the “Company”) (NYSE: ZEPP) today reported revenues of US$42.5 million; a basic and diluted net loss per share of US$0.05; and a basic and diluted net loss per ADS of US$0.82 for the third quarter ended September 30, 2024; |
|
| November 12, 2024 |
SC 13G/A 1 tm2428164d1sc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No.3)* Zepp Health Corporation (Name of Issuer) Class A ordinary shares, $0.0001 par value per share (Title of Class of Securities) 98945L204 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of this |
|
| October 4, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 5) Zepp Health Corp (Name of Issuer) SPONSORED ADS (Title of Class of Securities) 98945L204 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Sched |
|
| October 4, 2024 |
Zepp Regains Compliance with NYSE Minimum Price Continued Listing Criterion Exhibit 99.1 Zepp Regains Compliance with NYSE Minimum Price Continued Listing Criterion MILPITAS, Calif., October 2, 2024 /PRNewswire/ - Zepp Health Corporation (“Zepp Health” or the “Company”) (NYSE: ZEPP), a global leader in smart wearables and health technology, today announced that it has received a letter from the New York Stock Exchange (“NYSE”) dated October 2, 2024 (the “October Letter”), |
|
| October 4, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of October 2024 Commission File Number: 001-38369 Zepp Health Corporation (Registrant’s Name) Huami Global Innovation Center Building B2, Zhong’an Chuanggu Technology Park No. 900 Wangjiang West R |
|
| October 4, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 4) Zepp Health Corp (Name of Issuer) SPONSORED ADS (Title of Class of Securities) 98945L105 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Sched |
|
| September 16, 2024 |
AMENDMENT NO. 1 TO THE DEPOSIT AGREEMENT AMENDMENT NO. 1 TO THE DEPOSIT AGREEMENT THIS AMENDMENT NO.1 dated as of September 16, 2024 (the “Effective Date”) to the Deposit Agreement, dated as of February 7, 2018, (the “Deposit Agreement”), by and among (i) Zepp Health Corporation, a company incorporated under the laws of the Cayman Islands, with its principal executive office at Huami Global Innovation Center, Building B2, Zhong’an Chuang |
|
| September 16, 2024 |
As filed with the Securities and Exchange Commission on September 16, 2024 Registration No. |
|
| September 16, 2024 |
Certification under Rule 466 The depositary, Deutsche Bank Trust Company Americas, represents and certifies the following: (1) That it previously had filed a registration statement on Form F-6 (Zepp Health Corporation, File No. |
|
| September 6, 2024 |
Zepp Health Corporation Announces Plan to Implement ADS Ratio Change Exhibit 99.1 Zepp Health Corporation Announces Plan to Implement ADS Ratio Change MILPITAS, Calif., September 6, 2024 /PRNewswire/ - Zepp Health Corporation (“Zepp Health” or the “Company”) (NYSE: ZEPP), a global leader in smart wearables and health technology, today announced that it will change the ratio of its American depositary shares (“ADSs”) to its Class A ordinary shares (the “ADS Ratio”) |
|
| September 6, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of September 2024 Commission File Number: 001-38369 Zepp Health Corporation (Registrant’s Name) Huami Global Innovation Center Building B2, Zhong’an Chuanggu Technology Park No. 900 Wangjiang West |
|
| September 4, 2024 |
Zepp Health Corporation Announces Board Changes Exhibit 99.1 Zepp Health Corporation Announces Board Changes MILPITAS, Calif., Sept. 3, 2024 /PRNewswire/ - Zepp Health Corporation (“Zepp Health” or the “Company”) (NYSE: ZEPP), a global leader in smart wearables and health technology, today announced that its board of directors (the “Board”) has appointed Mr. Alain Lam, Mr. Mike Yan Yeung, and Mr. Meihui Fan as new directors, effective from Sep. |
|
| September 4, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of September 2024 Commission File Number: 001-38369 Zepp Health Corporation (Registrant’s Name) Huami Global Innovation Center Building B2, Zhong’an Chuanggu Technology Park No. 900 Wangjiang West |
|
| August 22, 2024 |
Zepp Health Corporation Reports Second Quarter 2024 Unaudited Financial Results Exhibit 99.1 Zepp Health Corporation Reports Second Quarter 2024 Unaudited Financial Results MILPITAS, Calif., August 21, 2024 /PRNewswire/ - Zepp Health Corporation (“Zepp” or the “Company”) (NYSE: ZEPP) today reported revenues of US$40.6 million; a basic and diluted net loss per share of US$0.04; and a basic and diluted net loss per ADS of US$0.17 for the second quarter ended June 30, 2024; adju |
|
| August 22, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of August 2024 Commission File Number: 001-38369 Zepp Health Corporation (Registrant’s Name) Huami Global Innovation Center Building B2, Zhong’an Chuanggu Technology Park No. 900 Wangjiang West Ro |
|
| June 27, 2024 |
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM Exhibit 15.3 CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM We consent to the incorporation by reference in Registration Statements No. 333-226665 and No. 333-269830 on Form S-8 of our report dated June 27, 2024, relating to the consolidated financial statements of Jiangsu Yitong High-tech Co., Ltd. included in this Amendment No. 1 to the Annual Report on Form 20-F for the year ended Dec |
|
| June 27, 2024 |
Exhibit 13.2 Certification by the Chief Financial Officer Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 In connection with the Annual Report of Zepp Health Corporation (the “Company”) on Form 20-F for the fiscal year ended December 31, 2023 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Leon Cheng Deng, Chief Financial Officer of the Company, |
|
| June 27, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 20-F/A (Amendment No. 1) (Mark One) ¨ REGISTRATION STATEMENT PURSUANT TO SECTION 12(B) OR 12(G) OF THE SECURITIES EXCHANGE ACT OF 1934 OR x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023. OR ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D |
|
| June 27, 2024 |
Exhibit 12.1 Certification by the Principal Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 I, Wang Wayne Huang, certify that: 1. I have reviewed this annual report on Form 20-F of Zepp Health Corporation (the “Company”); 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the |
|
| June 27, 2024 |
Exhibit 13.1 Certification by the Principal Executive Officer Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 In connection with the Annual Report of Zepp Health Corporation (the “Company”) on Form 20-F for the fiscal year ended December 31, 2023 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Wang Wayne Huang, Chief Executive Officer of the Com |
|
| June 27, 2024 |
Exhibit 12.2 Certification by the Chief Financial Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 I, Leon Cheng Deng, certify that: 1. I have reviewed this annual report on Form 20-F of Zepp Health Corporation (the “Company”); 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the state |
|
| May 22, 2024 |
Zepp Health Corporation Reports First Quarter 2024 Unaudited Financial Results Exhibit 99.1 Zepp Health Corporation Reports First Quarter 2024 Unaudited Financial Results MILPITAS, Calif., May 20, 2024 /PRNewswire/ - Zepp Health Corporation (“Zepp” or the “Company”) (NYSE: ZEPP) today reported revenues of US$39.8 million; a basic and diluted net loss per share of US$0.06; and a basic and diluted net loss per ADS of US$0.23 for the first quarter ended March 31, 2024; adjusted |
|
| May 22, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2024 Commission File Number: 001-38369 Zepp Health Corporation (Registrant’s Name) Huami Global Innovation Center Building B2, Zhong’an Chuanggu Technology Park No. 900 Wangjiang West Road |
|
| April 23, 2024 |
Exhibit 12.1 Certification by the Principal Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 I, Wang Huang, certify that: 1. I have reviewed this annual report on Form 20-F of Zepp Health Corporation (the “Company”); 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statem |
|
| April 23, 2024 |
Exhibit 13.2 Certification by the Chief Financial Officer Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 In connection with the Annual Report of Zepp Health Corporation (the “Company”) on Form 20-F for the fiscal year ended December 31, 2023 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Leon Cheng Deng, Chief Financial Officer of the Company, |
|
| April 23, 2024 |
Exhibit 13.1 Certification by the Principal Executive Officer Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 In connection with the Annual Report of Zepp Health Corporation (the “Company”) on Form 20-F for the fiscal year ended December 31, 2023 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Wang Huang, Chief Executive Officer of the Company, |
|
| April 23, 2024 |
Exhibit12.2 Certification by the Chief Financial Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 I, Leon Cheng Deng, certify that: 1. I have reviewed this annual report on Form 20-F of Zepp Health Corporation (the “Company”); 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statem |
|
| April 23, 2024 |
ZEPP HEALTH CORPORATION CLAWBACK POLICY Exhibit 97.1 ZEPP HEALTH CORPORATION CLAWBACK POLICY The Compensation Committee (the “Committee”) of the Board of Directors (the “Board”) of Zepp Health Corporation (the “Company”) believes that it is appropriate for the Company to adopt this Clawback Policy (the “Policy”) to be applied to the Executive Officers of the Company and adopts this Policy to be effective as of the Effective Date. 1. Def |
|
| April 23, 2024 |
Exhibit 4.19 THE SYMBOL “[***]” DENOTES PLACES WHERE CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THE EXHIBIT BECAUSE IT IS BOTH (i) NOT MATERIAL, AND (ii) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL Technology Transfer Agreement This Technology Transfer Agreement (this “Agreement”) is entered into by and between the following parties on September 28, 2023 (“Agreemen |
|
| April 23, 2024 |
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM Exhibit 15.1 CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM We consent to the incorporation by reference in Registration Statement Nos. 333-226665 and 333-269830 on Form S-8 of our report dated April 23, 2024, relating to the financial statements of Zepp Health Corporation appearing in this Annual Report on Form 20-F for the year ended December 31, 2023. /s/ Deloitte Touche Tohmatsu Cert |
|
| April 23, 2024 |
Exhibit 15.2 CONSENT LETTER To Zepp Health Corporation Huami Global Innovation Center Building B2, Zhong’an Chuanggu Technology Park No. 900 Wangjiang West Road Hefei, 230088 People’s Republic of China April 23, 2024 Dear Sir/Madam: We hereby consent to the reference of our name under the headings “Item 3. Key Information—D. Risk Factors—Risks Related to Our Corporate Structure” and “Item 4. Infor |
|
| April 23, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 20-F Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 20-F (Mark One) ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(B) OR 12(G) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023. OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) |
|
| March 19, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of March 2024 Commission File Number: 001-38369 Zepp Health Corporation (Registrant’s Name) Huami Global Innovation Center Building B2, Zhong’an Chuanggu Technology Park No. 900 Wangjiang West Roa |
|
| March 19, 2024 |
Zepp Health Corporation Reports Fourth Quarter and Full Year 2023 Unaudited Financial Results Exhibit 99.1 Zepp Health Corporation Reports Fourth Quarter and Full Year 2023 Unaudited Financial Results MILPITAS, Calif., March 18, 2024 /PRNewswire/ - Zepp Health Corporation (“Zepp” or the “Company”) (NYSE: ZEPP) today reported revenues of US$84.5 million (RMB0.6 billion); a basic and diluted net loss per share of US$0.005 (RMB0.03); and a basic and diluted net loss per ADS of US$0.02 (RMB0.1 |
|
| January 19, 2024 |
SC 13G/A 1 tm243520d1sc13ga.htm SC 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) Information to Be Included in Statements Filed Pursuant to § 240.13d-1 (b), (c) and (d) and Amendments Thereto Filed Pursuant to § 240.13d-2 UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 6)* Zepp Health Corporation (Name of Issuer) Class A ordinary shares, par v |
|
| January 12, 2024 |
SC 13G/A 1 Zepp20231231.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 3) Zepp Health Corp (Name of Issuer) SPONSORED ADS (Title of Class of Securities) 98945L105 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule p |
|
| November 21, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November 2023 Commission File Number: 001-38369 Zepp Health Corporation (Registrant’s Name) Huami Global Innovation Center Building B2, Zhong’an Chuanggu Technology Park No. 900 Wangjiang West |
|
| November 21, 2023 |
Zepp Health Corporation Reports Third Quarter 2023 Unaudited Financial Results Exhibit 99.1 Zepp Health Corporation Reports Third Quarter 2023 Unaudited Financial Results Amsterdam, the Netherlands, November 20, 2023 /PRNewswire/ - Zepp Health Corporation (“Zepp” or the “Company”) (NYSE: ZEPP) today reported revenues of RMB0.6 billion (US$82.5 million); a basic and diluted net income per share of RMB0.01 (US$0.002); and a basic and diluted net income per ADS of RMB0.05 (US$0 |
|
| September 28, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of September 2023 Commission File Number: 001-38369 Zepp Health Corporation (Registrant’s Name) Huami Global Innovation Center Building B2, Zhong’an Chuanggu Technology Park No. 900 Wangjiang West |
|
| August 22, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of August 2023 Commission File Number: 001-38369 Zepp Health Corporation (Registrant’s Name) Huami Global Innovation Center Building B2, Zhong’an Chuanggu Technology Park No. 900 Wangjiang West Ro |
|
| August 22, 2023 |
Zepp Health Corporation Reports Second Quarter 2023 Unaudited Financial Results Exhibit 99.1 Zepp Health Corporation Reports Second Quarter 2023 Unaudited Financial Results AMSTERDAM, August 21, 2023 /PRNewswire/ - Zepp Health Corporation (“Zepp” or the “Company”) (NYSE: ZEPP) today reported revenues of RMB0.65 billion (US$89.4 million); a basic and diluted net loss per share of RMB0.29 (US$0.04); and a basic and diluted net loss per ADS of RMB1.15 (US$0.16) for the second qu |
|
| June 5, 2023 |
Zepp Health Corporation Huami Global Innovation Center Building B2, Zhong’an Chuanggu Technology Park No. |
|
| May 24, 2023 |
6-K 1 tm2316547d16k.htm FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2023 Commission File Number: 001-38369 Zepp Health Corporation (Registrant’s Name) Huami Global Innovation Center Building B2, Zhong’an Chuanggu Technology |
|
| May 24, 2023 |
Zepp Health Corporation Reports First Quarter 2023 Unaudited Financial Results Exhibit 99.1 Zepp Health Corporation Reports First Quarter 2023 Unaudited Financial Results BEIJING, May 23, 2023 /PRNewswire/ - Zepp Health Corporation (“Zepp” or the “Company”) (NYSE: ZEPP) today reported revenues of RMB0.6 billion (US$93.9 million); a GAAP basic and diluted net loss per share of RMB0.56 (US$0.08); and a GAAP basic and diluted net loss per ADS of RMB2.23 (US$0.32) for the first |
|
| April 24, 2023 |
Exhibit 15.2 CONSENT LETTER To Zepp Health Corporation Building B2, Zhong’an Chuanggu Technology Park No. 900 Wangjiang West Road, Hefei, 230088 People’s Republic of China April 24, 2023 Dear Sir/Madam: We hereby consent to the reference of our name under the headings “Item 3. Key Information—D. Risk Factors—Risks Related to Our Corporate Structure” and “Item 4. Information on the Company—C. Organ |
|
| April 24, 2023 |
CEO Certification Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 Exhibit 12.1 Certification by the Principal Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 I, Wang Huang, certify that: 1. I have reviewed this annual report on Form 20-F of Zepp Health Corporation (the “Company”); 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statem |
|
| April 24, 2023 |
Consent of Deloitte Touche Tohmatsu Certified Public Accountants LLP Exhibit 15.1 CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM We consent to the incorporation by reference in Registration Statements No. 333-226665 and No. 333-269830 on Form S-8 of our report dated April 24, 2023, relating to the financial statements of Zepp Health Corporation appearing in this Annual Report on Form 20-F for the year ended December 31, 2022. /s/ Deloitte Touche Tohmatsu |
|
| April 24, 2023 |
Exhibit 4.21 Business Cooperation Agreement Party A: Xiaomi Communication Technology Co., Ltd. Legal Representative: Wang Chuan Address: No. 019, 9th Floor, Building 6, Yard 33, Xierqi Middle Road, Haidian District, Beijing Party B: Anhui Huami Information Technology Co., Ltd. Legal Representative: Huang Wang Address: Building B2, Zhong’an Chuanggu Science and Technology Park, High-tech Developmen |
|
| April 24, 2023 |
CEO Certification Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 Exhibit 13.1 Certification by the Principal Executive Officer Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 In connection with the Annual Report of Zepp Health Corporation (the “Company”) on Form 20-F for the fiscal year ended December 31, 2022 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Wang Huang, Chief Executive Officer of the Company, |
|
| April 24, 2023 |
CFO Certification Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 Exhibit 12.2 Certification by the Chief Financial Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 I, Leon Cheng Deng, certify that: 1. I have reviewed this annual report on Form 20-F of Zepp Health Corporation (the “Company”); 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the state |
|
| April 24, 2023 |
Second Amended and Restated Memorandum and Articles of Association of the Registrant, as amended Exhibit 1.1 Registrar of Companies Government Administration Building 133 Elgin Avenue George Town Grand Cayman Huami Corporation (ROC # 294742) (the “Company”) TAKE NOTICE that at the 2020 annual general meeting of the shareholders of the Company dated 25 February 2021, the following special resolutions were passed: IT IS RESOLVED, as a special resolution: THAT the change of the Company’s legal n |
|
| April 24, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of April 2023 Commission File Number: 001-38369 Zepp Health Corporation (Registrant’s Name) Huami Global Innovation Center Building B2, Zhong’an Chuanggu Technology Park No. 900 Wangjiang West Roa |
|
| April 24, 2023 |
CFO Certification Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 Exhibit 13.2 Certification by the Chief Financial Officer Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 In connection with the Annual Report of Zepp Health Corporation (the “Company”) on Form 20-F for the fiscal year ended December 31, 2022 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Leon Cheng Deng, Chief Financial Officer of the Company, |
|
| April 24, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 20-F Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 20-F (Mark One) ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(B) OR 12(G) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022. OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) |
|
| March 22, 2023 |
Zepp Health Corporation Reports Fourth Quarter and Full Year 2022 Unaudited Financial Results Exhibit 99.1 Zepp Health Corporation Reports Fourth Quarter and Full Year 2022 Unaudited Financial Results BEIJING, CHINA, March 21, 2023 /PRNewswire/ - Zepp Health Corporation (“Zepp” or the “Company”) (NYSE: ZEPP) today reported revenues of RMB1.1 billion (US$155.4 million); a GAAP basic and diluted net loss per share of RMB0.31 (US$0.04); and a GAAP basic and diluted net loss per ADS of RMB1.23 |
|
| March 22, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of March 2023 Commission File Number: 001-38369 Zepp Health Corporation (Registrant’s Name) Huami Global Innovation Center Building B2, Zhong’an Chuanggu Technology Park No. 900 Wangjiang West Roa |
|
| February 16, 2023 |
Exhibit 107.1 Calculation of Filing Fee Table Form S-8 (Form Type) Zepp Health Corporation (Exact Name of Registrant as Specified in its Charter) Newly Registered Securities Security Type Security Class Title(1) Fee Calculation Rule Amount Registered(2) Proposed Maximum Offering Price Per Share Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee(1) Equity Class A ordinary shares, |
|
| February 16, 2023 |
As filed with the Securities and Exchange Commission on February 16, 2023 As filed with the Securities and Exchange Commission on February 16, 2023 Registration No. |
|
| February 1, 2023 |
ZEPP / Zepp Health Corporation / FRANKLIN RESOURCES INC Passive Investment zepp22a2.htm - Generated by SEC Publisher for SEC Filing CUSIP NO. 98945L105 13G Page 1 of 14 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No.2)* ZEPP HEALTH CORPORATION (Name of Issuer) American depositary shares (each representing four Class A ordinary shares Class A ordinary shares, par value US$0.0001 |
|
| February 1, 2023 |
ZEPP / Zepp Health Corporation / Huang Wang - SC 13G/A Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) Information to Be Included in Statements Filed Pursuant to § 240.13d-1 (b), (c) and (d) and Amendments Thereto Filed Pursuant to § 240.13d-2 UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 5)* Zepp Health Corporation (Name of Issuer) Class A ordinary shares, par value of $0.0001 per share (Title of Class |
|
| January 20, 2023 |
Zepp Health Corporation Huami Global Innovation Center Building B2, Zhong’an Chuanggu Technology Park No. |
|
| January 12, 2023 |
ZEPP / Zepp Health Corporation / Allspring Global Investments Holdings, LLC Passive Investment SC 13G/A 1 Zepp.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2) Zepp Health Corp (Name of Issuer) SPONSORED ADS (Title of Class of Securities) 98945L105 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant |
|
| January 11, 2023 |
ZEPP HEALTH CORPORATION 2023 SHARE INCENTIVE PLAN Article 1 Exhibit 99.1 ZEPP HEALTH CORPORATION 2023 SHARE INCENTIVE PLAN Article 1 PURPOSE The purpose of this 2023 Share Incentive Plan (the “Plan”) is to promote the success and enhance the value of Zepp Health Corporation, an exempted company formed under the laws of the Cayman Islands (the “Company”), by linking the personal interests of the Directors, Employees, and Consultants to those of the Company’ |
|
| January 11, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of January 2023 Commission File Number: 001-38369 Zepp Health Corporation Huami Global Innovation Center Building B2, Zhong’an Chuanggu Technology Park No. 900 Wangjiang West Road Hefei, 230088 Pe |
|
| November 22, 2022 |
Zepp Health Corporation Reports Third Quarter 2022 Unaudited Financial Results Exhibit 99.1 Zepp Health Corporation Reports Third Quarter 2022 Unaudited Financial Results BEIJING, November 21, 2022 /PRNewswire/ - Zepp Health Corporation (?Zepp? or the ?Company?) (NYSE: ZEPP) today reported revenues of RMB1.2 billion (US$169.5 million); a GAAP diluted net loss per share of RMB0.07 (US$0.01); and a GAAP diluted net loss per ADS of RMB0.28 (US$0.04) for the third quarter ended |
|
| November 22, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November 2022 Commission File Number: 001-38369 Zepp Health Corporation Huami Global Innovation Center Building B2, Zhong’an Chuanggu Technology Park No. 900 Wangjiang West Road Hefei, 230088 P |
|
| November 14, 2022 |
Zepp Health Corporation Huami Global Innovation Center Building B2, Zhong’an Chuanggu Technology Park No. |
|
| October 31, 2022 |
Zepp Health Corporation Huami Global Innovation Center Building B2, Zhong’an Chuanggu Technology Park No. |
|
| September 14, 2022 |
Zepp Health Corporation Huami Global Innovation Center Building B2, Zhong’an Chuanggu Technology Park No. |
|
| September 14, 2022 |
As of December 31, 2021 See Footnotes for details about the assets and calculations reflected under each column. |
|
| August 30, 2022 |
Zepp Health Corporation Huami Global Innovation Center Building B2, Zhong’an Chuanggu Technology Park No. |
|
| August 26, 2022 |
Zepp Health Corporation Reports Second Quarter 2022 Unaudited Financial Results Exhibit 99.1 Zepp Health Corporation Reports Second Quarter 2022 Unaudited Financial Results BEIJING, August 25, 2022 /PRNewswire/ - Zepp Health Corporation (?Zepp? or the ?Company?) (NYSE: ZEPP) today reported revenues of RMB1.1 billion (US$165.5 million); GAAP diluted net loss per share of RMB0.44 (US$0.07); and GAAP diluted net loss per ADS of RMB1.74 (US$0.26) for the second quarter ended June |
|
| August 26, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of August 2022 Commission File Number: 001-38369 Zepp Health Corporation Huami Global Innovation Center Building B2, Zhong?an Chuanggu Technology Park No. 900 Wangjiang West Road Hefei, 230088 Peo |
|
| June 15, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of June 2022 Commission File Number: 001-38369 Zepp Health Corporation (Registrant?s Name) Huami Global Innovation Center Building B2, Zhong?an Chuanggu Technology Park No. 900 Wangjiang West Road |
|
| June 15, 2022 |
Exhibit 99.2 ZEPP HEALTH CORPORATION (Incorporated in the Cayman Islands with limited liability) (NYSE Ticker: ZEPP) NOTICE OF ANNUAL GENERAL MEETING To Be Held on July 5, 2022 (or any adjourned or postponed meeting thereof) NOTICE IS HEREBY GIVEN that an Annual General Meeting (?AGM?) of Zepp Health Corporation (the ?Company?) will be held at 7/F, Building B2, Zhongguancun No. 1, No.81 Beiqing Ro |
|
| June 15, 2022 |
Zepp Health Corporation to Hold Annual General Meeting on July 5, 2022 Exhibit 99.1 Zepp Health Corporation to Hold Annual General Meeting on July 5, 2022 BEIJING, June 14, 2022 /PRNewswire/ - Zepp Health Corporation, ("Zepp Health", the "Company" or "we") (NYSE: ZEPP), a cloud-based healthcare services provider with world-leading smart wearable technology, today announced that it will hold its annual general meeting of shareholders (the "AGM") at 7/F, Building B2, Z |
|
| May 25, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2022 Commission File Number: 001-38369 Zepp Health Corporation Huami Global Innovation Center Building B2, Zhong?an Chuanggu Technology Park No. 900 Wangjiang West Road Hefei, 230088 People |
|
| May 25, 2022 |
Zepp Health Corporation Reports First Quarter 2022 Unaudited Financial Results Exhibit 99.1 Zepp Health Corporation Reports First Quarter 2022 Unaudited Financial Results BEIJING, May 24, 2022 /PRNewswire/ - Zepp Health Corporation (?Zepp? or the ?Company?) (NYSE: ZEPP) today reported revenue of RMB0.8 billion (US$119.4 million); GAAP diluted net loss per share of RMB0.36 (US$0.06); and GAAP diluted net loss per ADS of RMB1.42 (US$0.22) for the first quarter ended March 31, |
|
| April 28, 2022 |
CFO Certification Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 Exhibit 12.2 Certification by the Chief Financial Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 I, Leon Cheng Deng, certify that: 1. I have reviewed this annual report on Form 20-F of Zepp Health Corporation (the “Company”); 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the state |
|
| April 28, 2022 |
CEO Certification Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 Exhibit 13.1 Certification by the Principal Executive Officer Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 In connection with the Annual Report of Zepp Health Corporation (the “Company”) on Form 20-F for the fiscal year ended December 31, 2021 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Wang Huang, Chief Executive Officer of the Company, |
|
| April 28, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 20-F Table of Contents ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. |
|
| April 28, 2022 |
Exhibit 15.2 CONSENT LETTER ? To Zepp Health Corporation ? ? Building B2, Zhong?an Chuanggu Technology Park ? ? No. 900 Wangjiang West Road, Hefei, 230088 ? ? People?s Republic of China ? April 28, 2022 ? Dear Sir/Madam: ? We hereby consent to the reference of our name under the headings ?Item 3. Key Information?D. Risk Factors?Risks Related to Our Corporate Structure? and ?Item 4. Information on |
|
| April 28, 2022 |
CFO Certification Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 Exhibit 13.2 Certification by the Chief Financial Officer Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 In connection with the Annual Report of Zepp Health Corporation (the “Company”) on Form 20-F for the fiscal year ended December 31, 2021 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Leon Cheng Deng, Chief Financial Officer of the Company, |
|
| April 28, 2022 |
CEO Certification Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 Exhibit 12.1 Certification by the Principal Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 I, Wang Huang, certify that: 1. I have reviewed this annual report on Form 20-F of Zepp Health Corporation (the “Company”); 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statem |
|
| April 28, 2022 |
Consent of Deloitte Touche Tohmatsu Certified Public Accountants LLP Exhibit 15.1 CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM We consent to the incorporation by reference in Registration Statement No. 333-226665 on Form S-8 and Registration Statement No. 333-230844 on Form F-3 of our report dated April 28, 2022, relating to the financial statements of Zepp Health Corporation appearing in this Annual Report on Form 20-F for the year ended December 31, 2 |
|
| March 18, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of March 2022 Commission File Number: 001-38369 Zepp Health Corporation Huami Global Innovation Center Building B2, Zhong?an Chuanggu Technology Park No. 900 Wangjiang West Road Hefei, 230088 Peop |
|
| March 18, 2022 |
Zepp Health Corporation Reports Fourth Quarter and Full Year 2021 Unaudited Financial Results Exhibit 99.1 Zepp Health Corporation Reports Fourth Quarter and Full Year 2021 Unaudited Financial Results BEIJING, March 17, 2022 /PRNewswire/ - Zepp Health Corporation (?Zepp? or the ?Company?) (NYSE: ZEPP) today reported revenue of RMB1.7 billion (US$260.7 million); GAAP diluted net income per share of RMB0.14 (US$0.02); and GAAP diluted net income per ADS of RMB0.55 (US$0.09) for the fourth qu |
|
| February 10, 2022 |
ZEPP / Zepp Health Corporation / Huang Wang - SC 13G/A Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) Information to Be Included in Statements Filed Pursuant to § 240.13d-1 (b), (c) and (d) and Amendments Thereto Filed Pursuant to § 240.13d-2 UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 4)* Zepp Health Corporation (Name of Issuer) Class A ordinary shares, par value of $0.0001 per share (Title of Class |
|
| February 3, 2022 |
ZEPP / Zepp Health Corporation / FRANKLIN RESOURCES INC Passive Investment zepp21a1.htm - Generated by SEC Publisher for SEC Filing CUSIP NO. 98945L105 13G Page 1 of 14 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* ZEPP HEALTH CORPORATION (Name of Issuer) American depositary shares (each representing four Class ordinary shares Class A ordinary shares, par value US$0.0001 p |
|
| January 28, 2022 |
ZEPP / Zepp Health Corporation / Huang Wang - SC 13G/A Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) Information to Be Included in Statements Filed Pursuant to ? 240.13d-1 (b), (c) and (d) and Amendments Thereto Filed Pursuant to ? 240.13d-2 UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 3)* Zepp Health Corporation (Name of Issuer) Class A ordinary shares, par value of $0.0001 per share (Title of Class |
|
| January 18, 2022 |
ZEPP / Zepp Health Corporation / Allspring Global Investments Holdings, LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. ) Zepp Health Corp (Name of Issuer) SPONSORED ADS (Title of Class of Securities) 98945L105 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedul |
|
| January 4, 2022 |
Zepp Health Provides Updates to Guidance and Share Repurchases Exhibit 99.1 Zepp Health Provides Updates to Guidance and Share Repurchases Beijing ? December 31, 2021 ? Zepp Health Corp. (NYSE: ZEPP) announced today an update to its guidance for the fourth quarter 2021, as well as an update to the progress of its share repurchase program. Due to greater than anticipated effects of Covid, including a more persistent worldwide chip shortage and newly increased |
|
| January 4, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of January 2022 Commission File Number: 001-38369 Zepp Health Corporation Huami Global Innovation Center Building B2, Zhong?an Chuanggu Technology Park No. 900 Wangjiang West Road Hefei, 230088 Pe |
|
| December 9, 2021 |
ZEPP / Zepp Health Corporation / Allspring Global Investments Holdings, LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. ) Zepp Health Corp (Name of Issuer) SPONSORED ADS (Title of Class of Securities) 98945L105 (CUSIP Number) November 30, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedul |
|
| December 8, 2021 |
ZEPP / Zepp Health Corporation / WELLS FARGO & COMPANY/MN Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 5) ZEPP HEALTH CORPORATION (Name of Issuer) SPONSORED ADS (Title of Class of Securities) 98945L105 (CUSIP Number) November 30, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this |
|
| November 17, 2021 |
Zepp Health Corporation Reports Third Quarter 2021 Unaudited Financial Results Exhibit 99.1 Zepp Health Corporation Reports Third Quarter 2021 Unaudited Financial Results BEIJING, November 16, 2021 /PRNewswire/ - Zepp Health Corporation (?Zepp? or the ?Company?) (NYSE: ZEPP) today reported revenue of RMB1.6 billion (US$249.3 million); GAAP diluted net income per share of RMB0.19 (US$0.03); and GAAP diluted net income per ADS of RMB0.74 (US$0.11) for the third quarter ended S |
|
| November 17, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November 2021 Commission File Number: 001-38369 Zepp Health Corporation Huami Global Innovation Center Building B2, Zhong?an Chuanggu Technology Park No. 900 Wangjiang West Road Hefei, 230088 P |
|
| August 20, 2021 |
Zepp Health Corporation Reports Second Quarter 2021 Unaudited Financial Results Exhibit 99.1 Zepp Health Corporation Reports Second Quarter 2021 Unaudited Financial Results BEIJING, August 19, 2021 /PRNewswire/ - Zepp Health Corporation (?Zepp? or the ?Company?) (NYSE: ZEPP) today reported revenue of RMB1.8 billion (US$284.2 million), an increase of 61.4% from the same period last year; GAAP diluted net income per share of RMB0.35 (US$0.05); and GAAP diluted net income per AD |
|
| August 20, 2021 |
Zepp Health Announces Appointment of Chief Technology Officer Exhibit 99.2 Zepp Health Announces Appointment of Chief Technology Officer Beijing, China ? August 19, 2021 ? Zepp Health Corporation ("Zepp Health" or the "Company") (NYSE: ZEPP) today announced that it has appointed Mr. Meihui Fan as the Company's Chief Technology Officer, effective on August 19, 2021. After his appointment as CTO, Mr. Fan will review and supervise the technical roadmap, key fun |
|
| August 20, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of August 2021 Commission File Number: 001-38369 Zepp Health Corporation Huami Global Innovation Center Building B2, Zhong’an Chuanggu Technology Park No. 900 Wangjiang West Road Hefei, 230088 Peo |
|
| July 12, 2021 |
ZEPP / Zepp Health Corporation / WELLS FARGO & COMPANY/MN Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 4) ZEPP HEALTH CORPORATION (Name of Issuer) SPONSORED ADS (Title of Class of Securities) 98945L105 (CUSIP Number) June 30, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Sch |
|
| May 14, 2021 |
Zepp Health Corp. Reports First Quarter 2021 Unaudited Financial Results Exhibit 99.1 Zepp Health Corp. Reports First Quarter 2021 Unaudited Financial Results BEIJING, May 13, 2021 /PRNewswire/ - Zepp Health Corp. (NYSE: ZEPP) today reported revenue of RMB1.1 billion (US$175.1 million); GAAP diluted net loss per share of RMB0.16 (US$0.02); and GAAP diluted net loss per ADS of RMB0.64 (US$0.10) for the first quarter ended March 31, 2021. Each ADS represents four (4) Cla |
|
| May 14, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2021 Commission File Number: 001-38369 Zepp Health Corporation Huami Global Innovation Center Building B2, Zhong?an Chuanggu Technology Park No. 900 Wangjiang West Road Hefei, 230088 People |
|
| April 19, 2021 |
CEO Certification Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 EXHIBIT 13.1 Certification by the Principal Executive Officer Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 In connection with the Annual Report of Zepp Health Corporation (the “Company”) on Form 20-F for the fiscal year ended December 31, 2020 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Wang Huang, Chief Executive Officer of the Company, |
|
| April 19, 2021 |
CEO Certification Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 ? EXHIBIT 12.1 Certification by the Principal Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 I, Wang Huang, certify that: 1. I have reviewed this annual report on Form 20-F of Zepp Health Corporation (the ?Company?); 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the stat |
|
| April 19, 2021 |
CFO Certification Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 ? EXHIBIT 12.2 Certification by the Principal Financial Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 I, Leon Cheng Deng, certify that: 1. I have reviewed this annual report on Form 20-F of Zepp Health Corporation (the ?Company?); 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the |
|
| April 19, 2021 |
CFO Certification Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 EXHIBIT 13.2 Certification by the Principal Financial Officer Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 In connection with the Annual Report of Zepp Health Corporation (the “Company”) on Form 20-F for the fiscal year ended December 31, 2020 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Leon Cheng Deng, Chief Financial Officer of the Comp |
|
| April 19, 2021 |
Table of Contents ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. |
|
| April 19, 2021 |
Consent of Deloitte Touche Tohmatsu Certified Public Accountants LLP EX-15.1 9 zepp-20201231xex15d1.htm EXHIBIT 15.1 Exhibit 15.1 CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM We consent to the incorporation by reference in Registration Statement No. 333-226665 on Form S-8 and Registration Statement No. 333-230844 on Form F-3 of our report dated April 19, 2021, relating to the financial statements of Zepp Health Corporation (formerly, Huami Corporation) |
|
| April 19, 2021 |
Exhibit 15.2 ? ? ? ? CONSENT LETTER ? To Zepp Health Corporation Huami Global Innovation Center Building B2, Zhong?an Chuanggu Technology Park No. 900 Wangjiang West Road, Hefei, 230088 People?s Republic of China April 19, 2021 ? Dear Sir/Madam: ? We hereby consent to the reference of our name under the headings ?Item 3. Key Information?D. Risk Factors?Risks Related to Our Corporate Structure? and |
|
| April 19, 2021 |
Exhibit 4.18 ? THE SYMBOL ?[***]? DENOTES PLACES WHERE CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THE EXHIBIT BECAUSE IT IS BOTH (i) NOT MATERIAL, AND (ii) WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF PUBLICLY DISCLOSED Product-related Strategic Cooperation Agreement Party A: Xiaomi Communications Co., Ltd. Address: No. 019, F/9, Building 6, 33 Xi?erqi Middle Road, Haidian Dist |
|
| April 19, 2021 |
? ? Exhibit 4.19 ? ? Share Transfer Agreement in Respect of Shares in Jiangsu Yitong High-tech Co., Ltd. ? between ? Wang Zhenhong ? and ? Anhui Shunyuan Xinke Management Consulting Partnership (LP) ? ? January 5, 2021 ? ? ? ? Table of Contents 1 Definitions 1 2 Share Transfer 3 3 Transfer Price 3 4 Payment of Security Deposit and First Installment of Transfer Price 4 5 Payment of the Second Insta |
|
| March 16, 2021 |
Zepp Health Corp. Reports Fourth Quarter and Full Year 2020 Unaudited Financial Results Exhibit 99.1 Zepp Health Corp. Reports Fourth Quarter and Full Year 2020 Unaudited Financial Results BEIJING, March 15, 2021 /PRNewswire/ - Zepp Health Corp. (NYSE: ZEPP) today reported revenue of RMB2.0 billion, or US$302.3 million; GAAP diluted net income per share of RMB0.44 (US$0.07), or GAAP diluted net income per ADS of RMB1.76 (US$0.27) for the fourth quarter ended December 31, 2020. The sm |
|
| March 16, 2021 |
Current Report of Foreign Issuer - FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of March 2021 Commission File Number: 001-38369 Zepp Health Corporation Huami Global Innovation Center Building B2, Zhong?an Chuanggu Technology Park No. 900 Wangjiang West Road Hefei, 230088 Peop |
|
| February 25, 2021 |
Exhibit 99.1 Huami Corporation Announces Name Change to Zepp Health New name reflects company’s expanding health technology portfolio and growth in industrial healthcare technology BEIJING and CUPERTINO, Calif., Feb. 25, 2021 /PRNewswire/ - Huami Corp. today announced it is changing its name internationally to Zepp Health Corp. (NYSE: ZEPP) and the ticker symbol of its American depositary shares l |
|
| February 25, 2021 |
Filed pursuant to Rule 424(b)(3) Registration Statement on Form F-6 Registration No. |
|
| February 25, 2021 |
Filed pursuant to Rule 424(b)(3) Registration Statement on Form F-6 Registration No. |
|
| February 25, 2021 |
Current Report of Foreign Issuer - 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of February 2021 Commission File Number: 001-38369 Zepp Health Corporation Building H8, No. 2800, Chuangxin Road Hefei, 230088 People?s Republic of China (Address of principal executive offices) I |
|
| February 12, 2021 |
SC 13G/A SCHEDULE 13G CUSIP No. 44331K103 Page 1 of 5 Pages UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* Huami Corporation (Name of Issuer) Class A ordinary shares, par value US$0.0001 per share (Title of Class of Securities) 44331K103 ** (CUSIP Number) December 31, 2020 (Date of the Event Which Re |
|
| February 11, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 3) HUAMI CORP (Name of Issuer) SPONSORED ADS (Title of Class of Securities) 44331K103 (CUSIP Number) December 31, 2020 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is |
|
| February 9, 2021 |
SCHEDULE 13G AMENDMENT NO. 2 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No.2)* Huami Corporation (Name of Issuer) Class A ordinary shares, $0.0001 par value per share (Title of Class of Securities) 44331K 103** (CUSIP Number) December 31, 2020 (Date of Event Which Requires Filing of this Statement) Check |
|
| February 4, 2021 |
FOR SECTION 13 AND 16 REPORTING OBLIGATIONS huam20in.htm - Generated by SEC Publisher for SEC Filing CUSIP NO. 44331K103 13G Page 1 of 14 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Huami Corporation (Name of Issuer) American depositary shares (each representing four Class A ordinary shares Class A ordinary shares, par value US$0.0001 per sh |
|
| February 4, 2021 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) Information to Be Included in Statements Filed Pursuant to § 240.13d-1 (b), (c) and (d) and Amendments Thereto Filed Pursuant to § 240.13d-2 UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 2)* Huami Corporation (Name of Issuer) Class A ordinary shares, par value of $0.0001 per share (Title of Class of Se |
|
| January 26, 2021 |
Exhibit 99.5 January 27, 2021 Huami Corporation Please be advised of the following Depositary’s Notice of Annual General Meeting of Shareholders: Depositary Receipt Information CUSIP: 44331K103 (DTC Eligible) ADS ISIN: US44331K1034 Country of Incorporation: Cayman Islands Meeting Details: Annual General Meeting at 2:00pm (Beijing time) at Building B2, Zhongguancun No.1, No.81 Beiqing Road, Haidian |
|
| January 26, 2021 |
Exhibit 99.4 Huami Corporation (Incorporated in the Cayman Islands with limited liability) (NYSE Ticker: HMI) Ballot for the Annual General Meeting Held on February 25, 2021 (or any adjourned or postponed meeting thereof) I/We of , being the registered holder of ordinary shares 1, par value US$0.0001 per share, of Huami Corporation (the “Company”), hereby cast my ballot as follows: No. RESOLUTION |
|
| January 26, 2021 |
Current Report of Foreign Issuer - 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of January 2021 Commission File Number: 001-38369 Huami Corporation Building H8, No. 2800, Chuangxin Road Hefei, 230088 People’s Republic of China (Address of principal executive offices) Indicate |
|
| January 26, 2021 |
Exhibit 99.6 - 0 ANNUAL GENERAL MEETING OF SHAREHOLDERS OF HUAMI CORPORATION (Continued and to be signed on the reverse side) ADD YOUR EMAIL ADDRESS ONLINE Add your email address to your online account at AST for 24/7 access to your account and enroll in eConsent to receive future materials electronically. Update your account today: For first time users setting up an account, follow the instructio |
|
| January 26, 2021 |
Huami Corporation to Hold 2020 Annual General Meeting on February 25, 2021 Exhibit 99.1 Huami Corporation to Hold 2020 Annual General Meeting on February 25, 2021 Beijing, January 22, 2021 /PRNewswire/ — Huami Corporation (“Huami” or the “Company”) (NYSE: HMI), today announced that it will hold its 2020 Annual General Meeting of Shareholders (the “AGM”) at Building B2, Zhongguancun No.1, No.81 Beiqing Road, Haidian District, Beijing, PRC 100094, at 2:00 pm (Beijing Time) |
|
| January 26, 2021 |
Exhibit 99.2 Huami Corporation (Incorporated in the Cayman Islands with limited liability) (NYSE Ticker: HMI) NOTICE OF ANNUAL GENERAL MEETING to be held on February 25, 2021 (or any adjourned or postponed meeting thereof) NOTICE IS HEREBY GIVEN that an annual general meeting (the “AGM”) of Yirendai Ltd. (the “Company”) will be held at Building B2, Zhongguancun No.1, No.81 Beiqing Road, Haidian Di |
|
| January 26, 2021 |
Exhibit 99.3 Huami Corporation (Incorporated in the Cayman Islands with limited liability) (NYSE Ticker: HMI) Form of Proxy for Annual General Meeting to Be Held on February 25, 2021 (or any adjourned or postponed meeting thereof) Introduction This form of proxy (the “Form of Proxy”) is furnished in connection with the solicitation by the board of directors of Huami Corporation (the “Board”), a Ca |
|
| January 7, 2021 |
Exhibit 99.1 Huami Enters in Definitive Agreement to Acquire a Minority Stake in Jiangsu Yitong High-Tech Co., Ltd. to expand the healthcare ecosystem for Chinese market BEIJING, Jan. 5, 2021 /PRNewswire/ - Huami Corp. (NYSE: HMI) today announced that it has entered into an agreement to acquired 29.99% of the outstanding shares of Jiangsu Yitong Hi-Tech Co., Ltd., (Shenzhen: 300211) for an aggrega |
|
| January 7, 2021 |
Current Report of Foreign Issuer - FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of January 2021 Commission File Number: 001-38369 Huami Corporation Building H8, No. 2800, Chuangxin Road Hefei, 230088 People’s Republic of China (Address of principal executive offices) Indicate |
|
| November 24, 2020 |
Huami Corporation Reports Third Quarter 2020 Unaudited Financial Results Exhibit 99.2 Huami Corporation Reports Third Quarter 2020 Unaudited Financial Results BEIJING, November 23, 2020 /PRNewswire/ — Huami Corporation (NYSE: HMI) today reported revenue of RMB2.2 billion, or US$329.2 million; GAAP diluted net income per share of RMB0.31 (US$0.05), or GAAP diluted net income per ADS of RMB1.24 (US$0.18) for the third quarter ended September 30, 2020. “Third quarter unit |
|
| November 24, 2020 |
Former Texas Instruments Executive, Bing Xie Joins Huami’s Board as Independent Director Exhibit 99.1 Former Texas Instruments Executive, Bing Xie Joins Huami’s Board as Independent Director BEIJING and CUPERTINO, Calif., Nov. 22, 2020 /PRNewswire/ — Huami Corp. (NYSE: HMI) today announced that it appointed Mr. Bing Xie, former Texas Instruments (TI) executive officer and senior vice president of worldwide sales and applications, as an independent director on Huami’s board. Mr. Xie wi |
|
| November 24, 2020 |
Current Report of Foreign Issuer - 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November 2020 Commission File Number: 001-38369 Huami Corporation Huami Global Innovation Center Building B2, Zhong’an Chuanggu Technology Park, No.900 Wangjiang West Road Hefei, 230088 People’ |
|
| September 1, 2020 |
Huami Corp. Announces Change of Chief Financial Officer, Effective October 1, 2020 Exhibit 99.1 Huami Corp. Announces Change of Chief Financial Officer, Effective October 1, 2020 Beijing, August 31, 2020 — Huami Corp. (NYSE: HMI) today announced that Mr. David Cui has tendered his resignation as Chief Financial Officer, effective October 1, 2020, for personal reasons. Mr. Cui will become a consultant to the company for a transitional period of time after his resignation as the C |
|
| September 1, 2020 |
Current Report of Foreign Issuer - 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of September 2020 Commission File Number: 001-38369 Huami Corporation Building H8, No. 2800, Chuangxin Road Hefei, 230088 People’s Republic of China (Address of principal executive offices) Indica |
|
| August 19, 2020 |
Exhibit 99.1 Huami Corporation Reports Second Quarter 2020 Unaudited Financial Results BEIJING, August 18, 2020 /PRNewswire/ — Huami Corporation (“Huami” or the “Company”) (NYSE: HMI) today reported revenue of RMB1.137 billion, or US$161.0 million; GAAP diluted net income per share of RMB0.05 (US$0.01), or GAAP diluted net income per ADS of RMB0.21 (US$0.03) for the second quarter ended June 30, 2 |
|
| August 19, 2020 |
Current Report of Foreign Issuer - 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of August 2020 Commission File Number: 001-38369 Huami Corporation Building H8, No. 2800, Chuangxin Road Hefei, 230088 People’s Republic of China (Address of principal executive offices) Indicate |
|
| July 8, 2020 |
HMI / Huami Corporation / Banyan Partners Fund I, L.p. - SC 13D/A Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 2)* HUAMI CORPORATION (Name of Issuer) Class A Ordinary Shares, par value US$0.0001 per share (Title of Class of Securities) 44331K103 (CUSIP Number) Banyan Partners Fund I, L.P. c/o Intertrust Corporate Services (Cayman) Limited, 190 Elgin Avenue, George To |
|
| May 13, 2020 |
Current Report of Foreign Issuer - 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2020 Commission File Number: 001-38369 Huami Corporation Building H8, No. 2800, Chuangxin Road Hefei, 230088 People’s Republic of China (Address of principal executive offices) Indicate by |
|
| May 13, 2020 |
Exhibit 99.1 Huami Corporation Reports First Quarter 2020 Unaudited Financial Results Quarterly Revenues up 36.1% to RMB1,088.5 Million, and Shipments up 35.7% YoY BEIJING, May 12, 2020 /PRNewswire/ — Huami Corporation (“Huami” or the “Company”) (NYSE: HMI), a cloud-based healthcare services provider with world-leading smart wearable technology, today announced its unaudited financial results for |
|
| April 24, 2020 |
Current Report of Foreign Issuer - 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of April 2020 Commission File Number: 001-38369 Huami Corporation Building H8, No. 2800, Chuangxin Road Hefei, 230088 People’s Republic of China (Address of principal executive offices) Indicate b |
|
| April 24, 2020 |
Huami Corporation Files 2019 Annual Report on Form 20-F EX-99.1 2 a20-36303ex99d1.htm EX-99.1 Exhibit 99.1 Huami Corporation Files 2019 Annual Report on Form 20-F BEIJING, April 23, 2020 /PRNewswire/ — Huami Corporation (“Huami” or the “Company”) (NYSE: HMI), a cloud-based healthcare services provider with world-leading smart wearable technology, today announced that it has filed its Annual Report on Form 20-F for the full year ended December 31, 2019 |
|
| April 23, 2020 |
Consent of Deloitte Touche Tohmatsu Certified Public Accountants LLP EXHIBIT 15.1 CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM We consent to the incorporation by reference in Registration Statement No. 333-226665 on Form S-8 and Registration Statement No. 333-230844 on Form F-3 of our report dated April 23, 2020, relating to the financial statements of Huami Corporation appearing in this Annual Report on Form 20-F for the year ended December 31, 2019. / |
|
| April 23, 2020 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 20-F (Mark One) o REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2019. OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) |
|
| April 23, 2020 |
Exhibit 4.8 SECOND AMENDED AND RESTATED EQUITY PLEDGE AGREEMENT This SECOND AMENDED AND RESTATED EQUITY PLEDGE AGREEMENT (this “Agreement”) is entered into on March 20, 2020 by and among: 1. THE SHAREHOLDERS WHOSE NAMES ARE SET OUT IN APPENDIX I (each a “Pledgor” and collectively the “Pledgors”) 2. SHUNYUAN KAIHUA (BEIJING) TECHNOLOGY CO., LTD. (the “Pledgee”) Registered address: Unit 206-2, Level |
|
| April 23, 2020 |
Exhibit 4.5 SECOND AMENDED AND RESTATED SHAREHOLDER VOTING PROXY AGREEMENT This SECOND AMENDED AND RESTATED SHAREHOLDER VOTING PROXY AGREEMENT (this “Agreement”) is entered into on March 20, 2020 by and among: 1. THE SHAREHOLDERS WHOSE NAMES ARE SET OUT IN APPENDIX I (each an “Shareholder” and collectively the “Shareholders”) 2. SHUNYUAN KAIHUA (BEIJING) TECHNOLOGY CO., LTD. (the “WFOE”) Registere |
|
| April 23, 2020 |
CFO Certification Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 EXHIBIT 13.2 Certification by the Chief Financial Officer Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 In connection with the Annual Report of Huami Corporation (the “Company”) on Form 20-F for the fiscal year ended December 31, 2019 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, David Cui, Chief Financial Officer of the Company, certify, pu |
|
| April 23, 2020 |
Exhibit 2.5 Description of rights of each class of securities registered under Section 12 of the Securities Exchange Act of 1934 (the “Exchange Act”) American Depositary Shares (“ADSs”) each representing four Class A ordinary shares of Huami Corporation, (the “we,” “us,” “our company” or “our”) are listed and traded on the New York Stock Exchange and, in connection with this listing (but not for t |
|
| April 23, 2020 |
Exhibit 4.11 SECOND AMENDED AND RESTATED EXCLUSIVE OPTION AGREEMENT This SECOND AMENDED AND RESTATED EXCLUSIVE OPTION AGREEMENT (this “Agreement”) is entered into on March 20, 2020 by and among: 1. THE SHAREHOLDERS WHOSE NAMES ARE SET OUT IN APPENDIX I (each an “Existing Shareholder” and collectively the “Existing Shareholders”) 2. SHUNYUAN KAIHUA (BEIJING) TECHNOLOGY CO., LTD. (the “WFOE”) Regist |
|
| April 23, 2020 |
EX-4.12 10 a20-36301ex4d12.htm EX-4.12 Exhibit 4.12 SECOND AMENDED AND RESTATED EXCLUSIVE OPTION AGREEMENT This SECOND AMENDED AND RESTATED EXCLUSIVE OPTION AGREEMENT (this “Agreement”) is entered into on March 20, 2020 by and among: 1. THE SHAREHOLDERS WHOSE NAMES ARE SET OUT IN APPENDIX I (each an “Existing Shareholder” and collectively the “Existing Shareholders”) 2. SHUNYUAN KAIHUA (BEIJING) T |
|
| April 23, 2020 |
CEO Certification Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 EXHIBIT 12.1 Certification by the Principal Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 I, Wang Huang, certify that: 1. I have reviewed this annual report on Form 20-F of Huami Corporation (the “Company”); 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements m |
|
| April 23, 2020 |
Exhibit 15.2 CONSENT LETTER To Huami Corporation Building H8, No. 2800, Chuangxin Road Hefei, 230088 People’s Republic of China April 23, 2020 Dear Sir/Madam: We hereby consent to the reference of our name under the headings “Item 3. Key Information—D. Risk Factors—Risks Related to Our Corporate Structure” and “Item 4. Information on the Company—C. Organizational Structure” in Huami Corporation’s |
|
| April 23, 2020 |
Exhibit 4.9 SECOND AMENDED AND RESTATED EXCLUSIVE CONSULTATION AND SERVICE AGREEMENT This SECOND AMENDED AND RESTATED EXCLUSIVE CONSULTATION AND SERVICE AGREEMENT is entered into on March 20, 2020 at Beijing, People’s Republic of China (the “PRC”), by and between: (1) SHUNYUAN KAIHUA (BEIJING) TECHNOLOGY CO., LTD., a wholly foreign-owned enterprise incorporated under the laws of the PRC with its r |
|
| April 23, 2020 |
Exhibit 4.6 SECOND AMENDED AND RESTATED SHAREHOLDER VOTING PROXY AGREEMENT This SECOND AMENDED AND RESTATED SHAREHOLDER VOTING PROXY AGREEMENT (this “Agreement”) is entered into on March 20, 2020 by and among: 1. THE SHAREHOLDERS WHOSE NAMES ARE SET OUT IN APPENDIX I (each an “Shareholder” and collectively the “Shareholders”) 2. SHUNYUAN KAIHUA (BEIJING) TECHNOLOGY CO., LTD. (the “WFOE”) Registere |
|
| April 23, 2020 |
EX-4.10 8 a20-36301ex4d10.htm EX-4.10 Exhibit 4.10 SECOND AMENDED AND RESTATED EXCLUSIVE CONSULTATION AND SERVICE AGREEMENT This SECOND AMENDED AND RESTATED EXCLUSIVE CONSULTATION AND SERVICE AGREEMENT is entered into on March 20, 2020 at Beijing, People’s Republic of China (the “PRC”), by and between: (1) SHUNYUAN KAIHUA (BEIJING) TECHNOLOGY CO., LTD., a wholly foreign-owned enterprise incorporat |
|
| April 23, 2020 |
CFO Certification Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 EXHIBIT 12.2 Certification by the Chief Financial Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 I, David Cui, certify that: 1. I have reviewed this annual report on Form 20-F of Huami Corporation (the “Company”); 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, |
|
| April 23, 2020 |
Exhibit 4.7 SECOND AMENDED AND RESTATED EQUITY PLEDGE AGREEMENT This SECOND AMENDED AND RESTATED EQUITY PLEDGE AGREEMENT (this “Agreement”) is entered into on March 20, 2020 by and among: 1. THE SHAREHOLDERS WHOSE NAMES ARE SET OUT IN APPENDIX I (each a “Pledgor” and collectively the “Pledgors”) 2. SHUNYUAN KAIHUA (BEIJING) TECHNOLOGY CO., LTD. (the “Pledgee”) Registered address: Unit 206-2, Level |
|
| April 23, 2020 |
CEO Certification Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 EXHIBIT 13.1 Certification by the Principal Executive Officer Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 In connection with the Annual Report of Huami Corporation (the “Company”) on Form 20-F for the fiscal year ended December 31, 2019 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Wang Huang, Chief Executive Officer of the Company, certif |
|
| March 16, 2020 |
HMI / Huami Corporation 6-K - Current Report of Foreign Issuer - 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of March 2020 Commission File Number: 001-38369 Huami Corporation Building H8, No. 2800, Chuangxin Road Hefei, 230088 People’s Republic of China (Address of principal executive offices) Indicate b |
|
| March 16, 2020 |
Exhibit 99.1 Huami Corporation Reports Fourth Quarter and Full Year 2019 Unaudited Financial Results Quarterly Revenues up 72.4% to RMB2,111.4 Million, and Shipments up 59.8% YoY Annually Revenues up 59.4% to RMB5,812.3 Million, and Shipments up 53.8% YoY BEIJING, March 13, 2020 /PRNewswire/ — Huami Corporation (“Huami” or the “Company”) (NYSE: HMI), a cloud-based healthcare services provider with |
|
| February 14, 2020 |
HMI / Huami Corporation / GIC Private Ltd - SC 13G/A Passive Investment SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1) * Huami Corporation (Name of Issuer) Class A ordinary shares, par value US$0.0001 per share (Title of Class of Securities) 44331K103 (CUSIP Number) December 31, 2019 (Date of the Event Which Requires Filing of this Statement) Check the appropriat |
|
| February 13, 2020 |
HMI / Huami Corporation / Huang Wang - SC 13G/A Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G (Rule 13d-102) Information to Be Included in Statements Filed Pursuant to § 240. |
|
| February 12, 2020 |
HMI / Huami Corporation / Shunwei China Internet Fund Ii, L.p. - SC 13G/A Passive Investment SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No.1)* Huami Corporation (Name of Issuer) Class A ordinary shares, $0.0001 par value per share (Title of Class of Securities) 44331K 103** (CUSIP Number) December 31, 2019 (Date of Event Which Requires Filing of this Statement) Check the appropriate box |
|
| February 4, 2020 |
HMI / Huami Corporation / WELLS FARGO & COMPANY/MN Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2) HUAMI CORP (Name of Issuer) SPONSORED ADS (Title of Class of Securities) 44331K103 (CUSIP Number) December 31, 2019 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is |
|
| December 6, 2019 |
EX-99.1 Exhibit 99.1 Huami Corporation Announced Corporate Mission: Connect Health with Technology Recaps 2019 Accomplishments and Looks to 2020 and Beyond BEIJING, Dec. 4, 2019 /PRNewswire/ — Huami Corporation (“Huami” or the “Company”) (NYSE: HMI), a biometric and activity data-driven company with significant expertise in smart wearable technology, today hosted an annual press conference in Beij |
|
| December 6, 2019 |
HMI / Huami Corporation 6-K - Current Report of Foreign Issuer - FORM 6-K Form 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of December 2019 Commission File Number: 001-38369 Huami Corporation Building H8, No. 2800, Chuangxin Road Hefei, 230088 People’s Republic of China (Address of principal executive offices |
|
| November 29, 2019 |
EX-99.2 3 d827811dex992.htm EX-99.2 Exhibit 99.2 HUAMI CORPORATION (Incorporated in the Cayman Islands with limited liability) (NYSE Ticker: HMI) NOTICE OF ANNUAL GENERAL MEETING to Be Held on December 16, 2019 (or any adjourned or postponed meeting thereof) NOTICE IS HEREBY GIVEN that an annual general meeting (the “AGM”) of Huami Corporation (the “Company”) will be held at 30/F, China World Offi |
|
| November 29, 2019 |
HMI / Huami Corporation 6-K - Current Report of Foreign Issuer - FORM 6-K Form 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November 2019 Commission File Number: 001-38369 Huami Corporation Building H8, No. 2800, Chuangxin Road Hefei, 230088 People’s Republic of China (Address of principal executive offices |
|
| November 29, 2019 |
Huami Corporation to Hold 2019 Annual General Meeting on December 16, 2019 EX-99.1 Exhibit 99.1 Huami Corporation to Hold 2019 Annual General Meeting on December 16, 2019 BEIJING, November 28, 2019 /PRNewswire/ — Huami Corporation (“Huami” or the “Company”) (NYSE: HMI), a biometric and activity data-driven company with significant expertise in smart wearable technology, today announced that that it will hold its 2019 Annual General Meeting of Shareholders (the “AGM”) at |
|
| November 13, 2019 |
EX-99.1 Exhibit 99.1 Huami Corporation Reports Third Quarter 2019 Unaudited Financial Results Quarterly Revenues up 73.3% YoY to RMB1,862.5 Million, and Shipments up 67.1% YoY BEIJING, Nov. 12, 2019 /PRNewswire/ — Huami Corporation (“Huami” or the “Company”) (NYSE: HMI), a biometric and activity data-driven company with significant expertise in smart wearable technology, today announced its unaudi |
|
| November 13, 2019 |
HMI / Huami Corporation 6-K - Current Report of Foreign Issuer - FORM 6-K Form 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November 2019 Commission File Number: 001-38369 Huami Corporation Building H8, No. 2800, Chuangxin Road Hefei, 230088 People’s Republic of China (Address of principal executive offices |
|
| October 21, 2019 |
HMI / Huami Corporation / GIC Private Ltd - SC 13G Passive Investment SC 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. ) * Huami Corporation (Name of Issuer) Class A ordinary shares, par value US$0.0001 per share (Title of Class of Securities) 44331K103 (CUSIP Number) October 11, 2019 (Date of the Event Which Requires Filing of this Statement) Check the appropriate bo |
|
| September 3, 2019 |
HMI / Huami Corporation 6-K - Current Report of Foreign Issuer - FORM 6-K Form 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of September 2019 Commission File Number: 001-38369 Huami Corporation Building H8, No. 2800, Chuangxin Road Hefei, 230088 People’s Republic of China (Address of principal executive office |
|
| September 3, 2019 |
Huami Corporation Announces Change of Board Composition EX-99.1 Exhibit 99.1 Huami Corporation Announces Change of Board Composition BEIJING, China, August 30, 2019 /PRNewswire/ — Huami Corporation (“Huami” or the “Company”) (NYSE: HMI), a biometric and activity data-driven company with significant expertise in smart wearable technology, today announced the Mr. Tian Cheng and Mr. Bin Yue have resigned from the Board of Directors due to personal reasons |
|
| August 20, 2019 |
HMI / Huami Corporation 6-K - Current Report of Foreign Issuer - FORM 6-K Form 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of August 2019 Commission File Number: 001-38369 Huami Corporation Building H8, No. 2800, Chuangxin Road Hefei, 230088 People’s Republic of China (Address of principal executive offices) |
|
| August 20, 2019 |
EX-99.1 Exhibit 99.1 Huami Corporation Reports Second Quarter 2019 Unaudited Financial Results Quarterly Revenues up 36.6% Year-over-Year to RMB1,038.7 Million, Exceeding Guidance Range BEIJING, August 19, 2019 /PRNewswire/ — Huami Corporation (“Huami” or the “Company”) (NYSE: HMI), a biometric and activity data-driven company with significant expertise in smart wearable technology, today announce |
|
| June 5, 2019 |
HMI / Huami Corporation / Banyan Partners Fund I, L.p. - SC 13D/A Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 1)* HUAMI CORPORATION (Name of Issuer) Class A Ordinary Shares, par value US$0.0001 per share (Title of Class of Securities) 44331K103 (CUSIP Number) Banyan Partners Fund I, L.P. c/o Intertrust Corporate Services (Cayman) Limited, 190 Elgin Avenue, George To |
|
| June 5, 2019 |
EXHIBIT A JOINT FILING AGREEMENT In accordance with Rule 13d-1(k) promulgated under the Securities Exchange Act of 1934, as amended, the undersigned hereby agree to the joint filing with all other Reporting Persons (as such term is defined in the Schedule 13D referred to below) on behalf of each of them of a statement on Schedule 13D (including amendments thereto) with respect to the shares of Class A ordinary shares, par value of US$0. |
|
| June 4, 2019 |
EX-99.1 Exhibit 99.1 Huami Corporation Reports First Quarter 2019 Unaudited Financial Results Quarterly Revenues up 36.5% Year-over-Year to RMB799.6 Million, Exceeding Guidance Range BEIJING, June 3, 2019 /PRNewswire/ — Huami Corporation (“Huami” or the “Company”) (NYSE: HMI), a biometric and activity data-driven company with significant expertise in smart wearable technology, today announced its |
|
| June 4, 2019 |
HMI / Huami Corporation 6-K - Current Report of Foreign Issuer - FORM 6-K Form 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of June 2019 Commission File Number: 001-38369 Huami Corporation Building H8, No. 2800, Chuangxin Road Hefei, 230088 People’s Republic of China (Address of principal executive offices) In |
|
| April 25, 2019 |
Use these links to rapidly review the document TABLE OF CONTENTS Table of Contents Filed Pursuant to Rule 424(b)(4) Registration No. |
|
| April 25, 2019 |
HMI / Huami Corporation 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of April 2019 Commission File Number: 001-38369 Huami Corporation Building H8, No. 2800, Chuangxin Road Hefei, 230088 People’s Republic of China (Address of principal executive offices) Indicate b |
|
| April 25, 2019 |
Huami Corporation Announces Pricing of Follow-on Public Offering of American Depositary Shares Exhibit 99.2 Huami Corporation Announces Pricing of Follow-on Public Offering of American Depositary Shares BEIJING, China, April 25, 2019 /PRNewswire/ — Huami Corporation (“Huami” or the “Company”) (NYSE: HMI), a biometric and activity data-driven company with significant expertise in smart wearable technology, today announced the pricing of a registered follow-on public offering of 793,650 Ameri |
|
| April 25, 2019 |
Huami Corporation Announces Proposed Follow-on Public Offering of American Depositary Shares Exhibit 99.1 Huami Corporation Announces Proposed Follow-on Public Offering of American Depositary Shares BEIJING, China, April 24, 2019 /PRNewswire/ — Huami Corporation (“Huami” or the “Company”) (NYSE: HMI), a biometric and activity data-driven company with significant expertise in smart wearable technology, today announced the commencement of a proposed registered underwritten public offering b |
|
| April 23, 2019 |
Form of Underwriting Agreement Exhibit 1.1 [·] Class A Ordinary Shares Huami Corporation CLASS A ORDINARY SHARES, PAR VALUE US$0.0001 PER SHARE in the Form of American Depositary Shares UNDERWRITING AGREEMENT April [·], 2019 MORGAN STANLEY & CO. LLC CREDIT SUISSE SECURITIES (USA) LLC CITIGROUP GLOBAL MARKETS INC. As Representatives of the Several Underwriters c/o Morgan Stanley & Co. LLC 1585 Broadway New York, New York 10036, |
|
| April 23, 2019 |
Use these links to rapidly review the document TABLE OF CONTENTS Table of Contents As filed with the Securities and Exchange Commission on April 23, 2019 Registration No. |
|
| April 23, 2019 |
HMI / Huami Corporation CORRESP - - Morgan Stanley & Co. LLC 1585 Broadway New York, New York 10036 United States of America Credit Suisse Securities (USA) LLC Eleven Madison Avenue New York, New York 10010 United States of America Citigroup Global Markets Inc. 388 Greenwich Street New York, NY 10013 United States of America April 23, 2019 VIA EDGAR Mr. Jeff Kauten Ms. Barbara C. Jacobs Office of Information Technologies and Service |
|
| April 23, 2019 |
HMI / Huami Corporation CORRESP - - April 23, 2019 VIA EDGAR Ms. Barbara C. Jacobs, Assistant Director Mr. Jeff Kauten, Attorney-Advisor Division of Corporation Finance U.S. Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 U. S. A. Re: Huami Corporation (CIK No. 0001720446) Registration Statement on Form F-3 (File No. 333-230844) Dear Ladies and Gentlemen: Pursuant to Rule 461 of Regulation C (“Rule 461”) |
|
| April 12, 2019 |
Use these links to rapidly review the document TABLE OF CONTENTS Table of Contents As filed with the Securities and Exchange Commission on April 12, 2019 Registration No. |
|
| April 12, 2019 |
Exhibit 99.2 [Letterhead of Frost & Sullivan] April 9, 2019 Huami Corporation Building H8, No. 2800, Chuangxin Road Hefei 230088 People’s Republic of China Re: Consent of Frost & Sullivan (Beijing) Inc., Shanghai Branch Co. Ladies and Gentlemen, We understand that Huami Corporation (the “Company”) plans to file a registration statement on Form F-3 (the “Registration Statement”) with the United Sta |
|
| April 12, 2019 |
Opinion of Zhong Lun Law Firm regarding certain PRC tax matters (included in Exhibit 99.1) Exhibit 99.1 LEGAL OPINION To: Huami Corporation Building H8, No. 2800, Chuangxin Road Hefei, 230088 People’s Republic of China April 12, 2019 Dear Sir/Madam: 1. We are lawyers qualified in the People’s Republic of China (the “PRC”) and are qualified to issue opinions on the PRC Laws (as defined in Section 4). For the purpose of this legal opinion (this “Opinion”), the PRC does not include the Hon |
|
| April 12, 2019 |
CEO Certification Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 EXHIBIT 13.1 Certification by the Principal Executive Officer Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 In connection with the Annual Report of Huami Corporation (the “Company”) on Form 20-F for the fiscal year ended December 31, 2018 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Wang Huang, Chief Executive Officer of the Company, certif |
|
| April 12, 2019 |
Consent of Deloitte Touche Tohmatsu Certified Public Accountants LLP EXHIBIT 15.1 CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM We consent to the incorporation by reference in Registration Statement No.333-226665 on Form S-8 of our report dated April 12, 2019 relating to the consolidated financial statements and financial statement schedule of Huami Corporation, its subsidiaries, its consolidated variable interest entities (the “VIEs”) and its VIEs’ subs |
|
| April 12, 2019 |
CFO Certification Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 EXHIBIT 12.2 Certification by the Chief Financial Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 I, David Cui, certify that: 1. I have reviewed this annual report on Form 20-F of Huami Corporation (the “Company”); 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, |
|
| April 12, 2019 |
CFO Certification Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 EXHIBIT 13.2 Certification by the Chief Financial Officer Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 In connection with the Annual Report of Huami Corporation (the “Company”) on Form 20-F for the fiscal year ended December 31, 2018 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, David Cui, Chief Financial Officer of the Company, certify, pu |
|
| April 12, 2019 |
EXHIBIT 15.2 April 12, 2019 Huami Corporation Building H8, No. 2800, Chuangxin Road Hefei, 230088 People’s Republic of China Dear Sir/Madam: We hereby consent to the reference of our name under the headings the headings “Item 3. Key Information—D. Risk Factors—Risks Related to Our Corporate Structure” and “Item 4. Information on the Company—C. Organizational Structure” in Huami Corporation’s Annua |
|
| April 12, 2019 |
CEO Certification Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 EXHIBIT 12.1 Certification by the Principal Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 I, Wang Huang, certify that: 1. I have reviewed this annual report on Form 20-F of Huami Corporation (the “Company”); 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements m |
|
| April 12, 2019 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 20-F (Mark One) ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2018. OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) |
|
| April 12, 2019 |
HMI / Huami Corporation CORRESP - - SKADDEN, ARPS, SLATE, MEAGHER & FLOM 世達國際律師事務所 PARTNERS CHRISTOPHER W. BETTS GEOFFREY CHAN * ANDREW L. FOSTER * BRADLEY A. KLEIN ˜ CHI T. STEVE KWOK * EDWARD H.P. LAM ¨* HAIPING LI * RORY MCALPINE ¨ JONATHAN B. STONE * PALOMA P. WANG 42/F, EDINBURGH TOWER, THE LANDMARK 15 QUEEN’S ROAD CENTRAL, HONG KONG TEL: (852) 3740-4700 FAX: (852) 3740-4727 www.skadden.com AFFILIATE OFFICES BOSTON CHICAGO HOUS |
|
| April 8, 2019 |
HMI / Huami Corporation 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of April 2019 - Commission File Number: 001-38369 - Huami Corporation Building H8, No. 2800, Chuangxin Road Hefei, 230088 People’s Republic of China (Address of principal executive offices) Indica |
|
| March 15, 2019 |
HMI / Huami Corporation 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of March 2019 Commission File Number: 001-38369 Huami Corporation Building H8, No. 2800, Chuangxin Road Hefei, 230088 People’s Republic of China (Address of principal executive offices) Indicate b |
|
| March 15, 2019 |
Exhibit 99.1 Huami Corporation Reports Fourth Quarter and Full Year 2018 Unaudited Financial Results Quarterly Revenues up 62.7% Year-over-Year, Exceeding Guidance Range Full Year Revenues up 77.9% Year-over-Year to RMB3,645.3 Million BEIJING, March 14, 2019 /PRNewswire/ - Huami Corporation ("Huami" or the "Company") (NYSE: HMI), a biometric and activity data-driven company with significant expert |
|
| February 12, 2019 |
HMI / Huami Corporation 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of February 2019 - Commission File Number: 001-38369 - Huami Corporation Building H8, No. 2800, Chuangxin Road Hefei, 230088 People’s Republic of China (Address of principal executive offices) Ind |
|
| February 1, 2019 |
EX-99.(A) Exhibit A JOINT FILING AGREEMENT In accordance with Rule 13d-1(k) promulgated under the Securities Exchange Act of 1934, as amended, the undersigned hereby agree to the joint filing with all other Reporting Persons (as such term is defined in the Schedule 13G referred to below) on behalf of each of them of a statement on Schedule 13G (including amendments thereto) with respect to the sha |
|
| February 1, 2019 |
HMI / Huami Corporation / Xiaomi Corp - SC 13G Passive Investment SC 13G SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. )* Huami Corporation (Name of Issuer) Class A ordinary shares, $0.0001 par value per share (Title of Class of Securities) 44331K 103** (CUSIP Number) December 31, 2018 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate th |
|
| February 1, 2019 |
HMI / Huami Corporation / Shunwei China Internet Fund Ii, L.p. - SCHEDULE 13G Passive Investment SCHEDULE 13G SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. )* Huami Corporation (Name of Issuer) Class A ordinary shares, $0.0001 par value per share (Title of Class of Securities) 44331K 103** (CUSIP Number) December 31, 2018 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to design |
|
| February 1, 2019 |
HMI / Huami Corporation / Huang Wang - SC 13G Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G (Rule 13d-102) Information to Be Included in Statements Filed Pursuant to § 240. |
|
| February 1, 2019 |
EX-99.(A) EXHIBIT A JOINT FILING AGREEMENT In accordance with Rule 13d-1(k) promulgated under the Securities Exchange Act of 1934, as amended, the undersigned hereby agree to the joint filing with all other Reporting Persons (as such term is defined in the Schedule 13G referred to below) on behalf of each of them of a statement on Schedule 13G (including amendments thereto) with respect to the sha |
|
| January 22, 2019 |
HMI / Huami Corporation / WELLS FARGO & COMPANY/MN Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1) HUAMI CORP (Name of Issuer) SPONSORED ADS (Title of Class of Securities) 44331K103 (CUSIP Number) December 31, 2018 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is |
|
| November 27, 2018 |
Exhibit 99.1 Huami Corporation Reports Third Quarter 2018 Unaudited Financial Results Revenues up 126.7% Year-over-Year to RMB1,074.7 Million, Exceeding Guidance Range BEIJING, November 26, 2018 /PRNewswire/ - Huami Corporation ("Huami" or the "Company") (NYSE: HMI), a biometric and activity data-driven company with significant expertise in smart wearable technology, today announced its unaudited |
|
| November 27, 2018 |
HMI / Huami Corporation 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November 2018 Commission File Number: 001-38369 Huami Corporation Building H8, No. 2800, Chuangxin Road Hefei, 230088 People’s Republic of China (Address of principal executive offices) Indicat |
|
| November 13, 2018 |
HMI / Huami Corporation / WELLS FARGO & COMPANY/MN Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. ) HUAMI CORP (Name of Issuer) SPONSORED ADS (Title of Class of Securities) 44331K103 (CUSIP Number) October 31, 2018 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is fi |
|
| September 14, 2018 |
HMI / Huami Corporation / 3w Fund Management Ltd Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Huami Corporation (Name of Issuer) Class A Ordinary Shares, par value US$0.0001 per share American Depositary Shares (ADS), each representing Four Class A Ordinary Shares, par value $0.0001 per share (Title of Class of Securities) 44331K103 (CUSIP Number |
|
| August 21, 2018 |
EX-99.1 2 hmi-ex9916.htm EX-99.1 Exhibit 99.1 Huami Corporation Reports Second Quarter 2018 Unaudited Financial Results Revenues up 54.8% Year-over-Year to RMB760.1 Million, Exceeding Guidance Range BEIJING, August 20, 2018 /PRNewswire/ - Huami Corporation (“Huami” or the “Company”) (NYSE: HMI), a biometric and activity data-driven company with significant expertise in smart wearable technology, t |
|
| August 21, 2018 |
HMI / Huami Corporation 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of August 2018 - Commission File Number: 001-38369 - Huami Corporation Building H8, No. 2800, Chuangxin Road Hefei, 230088 People’s Republic of China (Address of principal executive offices) Indic |
|
| August 8, 2018 |
Exhibit 4.3 DEPOSIT AGREEMENT by and among HUAMI CORPORATION as Issuer, DEUTSCHE BANK TRUST COMPANY AMERICAS as Depositary, AND THE HOLDERS AND BENEFICIAL OWNERS OF AMERICAN DEPOSITARY SHARES EVIDENCED BY AMERICAN DEPOSITARY RECEIPTS ISSUED HEREUNDER Dated as of February 7, 2018 DEPOSIT AGREEMENT DEPOSIT AGREEMENT, dated as of February 7, 2018, by and among (i) Huami Corporation, a company incorpo |
|
| August 8, 2018 |
As filed with the Securities and Exchange Commission on August 8, 2018 Registration No. |
|
| June 8, 2018 |
HMI / Huami Corporation 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of June 2018 - Commission File Number: 001-38369 - Huami Corporation Building H8, No. 2800, Chuangxin Road Hefei, 230088 People’s Republic of China (Address of principal executive offices) Indicat |
|
| June 1, 2018 |
Huami Corporation Announces Official Launch of Mi Band 3 EX-99.1 2 hmi-ex9916.htm EX-99.1 Exhibit 99.1 Huami Corporation Announces Official Launch of Mi Band 3 BEIJING, May 31, 2018 /PRNewswire/ ━ Huami Corporation (“Huami” or the “Company”) (NYSE:HMI), a biometric and activity data-driven company with significant expertise in smart wearable technology, announced that the Mi Band 3 was officially launched today at the new product launch event of Xiaomi |
|
| June 1, 2018 |
HMI / Huami Corporation 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of June 2018 - Commission File Number: 001-38369 - Huami Corporation Building H8, No. 2800, Chuangxin Road Hefei, 230088 People's Republic of China (Address of principal executive offices) Indicat |
|
| May 22, 2018 |
HMI / Huami Corporation 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2018 Commission File Number: 001-38369 Huami Corporation Building H8, No. 2800, Chuangxin Road Hefei, 230088 People's Republic of China (Address of principal executive offices) Indicate by |
|
| May 22, 2018 |
EX-99.1 2 hmi-ex9916.htm EX-99.1 Exhibit 99.1 Huami Corporation Reports First Quarter 2018 Unaudited Financial Results Revenues up 77.0% Year-over-Year to RMB585.9 Million, Exceeding Guidance Range BEIJING, May 21, 2018 /PRNewswire/ - Huami Corporation (“Huami” or the “Company”) (NYSE: HMI), a biometric and activity data-driven company with significant expertise in smart wearable technology, today |
|
| April 27, 2018 |
CEO Certification Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 EXHIBIT 13.1 Certification by the Principal Executive Officer Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 In connection with the Annual Report of Huami Corporation (the “Company”) on Form 20-F for the fiscal year ended December 31, 2017 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Wang Huang, Chief Executive Officer of the Company, certif |
|
| April 27, 2018 |
CONSENT LETTER To Huami Corporation Building H8, No. 2800, Chuangxin Road Hefei, 230088 People’s Republic of China April 27, 2018 Dear Sir/Madam: We hereby consent to the reference of our name under the headings “Item 3. Key Information—D. Risk Factors—Risks Related to Our Corporate Structure” and “Item 4. Information on the Company—C. Organizational Structure” in Huami Corporation’s Annual Report |
|
| April 27, 2018 |
CFO Certification Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 EXHIBIT 13.2 Certification by the Principal Financial Officer Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 In connection with the Annual Report of Huami Corporation (the “Company”) on Form 20-F for the fiscal year ended December 31, 2017 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, David Cui, Chief Financial Officer of the Company, certify |
|
| April 27, 2018 |
CFO Certification Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 EXHIBIT 12.2 Certification by the Principal Financial Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 I, David Cui, certify that: 1. I have reviewed this annual report on Form 20-F of Huami Corporation; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of |
